Issue Date: November 24, 2008
Codexis And Dyadic Sign Enzymes Pact
Codexis, a Redwood City, Calif.-based biocatalyst technology developer, has licensed Dyadic International's Chrysosporium lucknowense fungus, or C1, expression system for the large-scale production of enzymes for making biofuels and chemical and pharmaceutical intermediates. Codexis will make an up-front payment of $10 million provided that certain performance criteria are satisfied. Based in Jupiter, Fla., Dyadic produces enzymes and other biomaterials using proprietary fungal strains.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society